AQST News and Press, Aquestive Therapeutics Inc. From 05/09/24

WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participa...

2024-05-08 12:32:09 ET Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Conference Call May 08, 2024 8:00 AM ET Company Participants Bennett Watson – ICR Westwicke Investor Relations Dan Barber – Chief Executive Officer and President Ernie Toth ...

2024-05-07 17:27:26 ET Aquestive Therapeutics press release ( NASDAQ: AQST ): Q1 GAAP EPS of -$0.17. Revenue of $12.05M (+8.3% Y/Y). Aquestive's full-year 2024 financial guidance is below.... The Company expects: Read the full article on Seeking Alpha ...

Met all endpoints in Phase 3 pivotal study for Anaphylm™ (epinephrine) Sublingual Film in first quarter 2024 when compared to EpiPen ® and other injectors used for the treatment of anaphylaxis On track to complete Anaphylm temperature/pH study in second quarter 2024 Receiv...

Aterian Inc. (ATER) is expected to report for Q1 2024 Dorman Products Inc. (DORM) is expected to report $0.82 for Q1 2024 Hillman Solutions Corp. (HLMN) is expected to report $0.08 for Q1 2024 Wake Forest Bancshares, Inc. (WAKE) is expected to report for quarter end 2024-03-31 Inn...

2024-04-29 13:56:26 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...

2024-04-29 10:02:54 ET More on Health Care Select Sector SPDR XLV: Pivotal Week Of Earnings For Healthcare Stocks XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance 19 out...

Libervant is the first and only FDA approved orally administered rescue product for the treatment of seizure clusters in patients ages 2 to 5 Announces immediate availability of Libervant 5mg, 7.5mg, 10mg, 12.5mg, and 15mg for patients between 2 to 5 years of age Company track r...

2024-04-27 08:09:56 ET More on Aquestive Therapeutics Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024 Aquestive Therapeutics, Inc. (AQST) Q4 2023 Earnings Call Transcript Aquestive Therapeutics, Inc. 2023 Q4 - Results - Earnings ...

WARREN, N.J., April 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technolo...